CSCO长期致力于开展临床肿瘤学继续教育和多中心协作研究,推动肿瘤诊断治疗的规范化,提高中国临床肿瘤学的学术水平。 2022中国临床肿瘤学会(CSCO)乳腺癌诊疗指南推荐多基因表达谱检测(21基因复发风险评估、70基因检测)、ER、PR、HER2、Ki-67分子特征检测、推荐PD-L1表达检测,同时推荐对遗传性乳腺高危患者进行遗传学咨询。
NCCN GUIDELINES ® 2022 FOR PATIENTS Breast Cancer Metastatic Presented with support from: Available online at NCCN.org/patients Ü Metastatic Breast Cancer Its easy to get lost in the cancer world Let NCCN Guidelines for Patients® be your guide 9 Step-by-step guides to the cancer ...
a.Lu D, Andersson TM, Fall K, et al. Clinical diagnosis of mental disorders immediately before and after cancer diagnosis: a nationwide matched cohort study in sweden. JAMA Oncol 2016;1188-1196. 焦虑、抑郁和精神创伤的筛查 (SANXDE-2) 英文版 中文版 脚注: b.患者对任何问题做肯定的回答,则需...
FDA批准药物:帕博利珠单抗 参考资料: 1.中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2022 2.NCCN Guidelines Version 4.2022 Breast Cancer. 作者:医世象 叶子
Imaging, 3rd bullet added:For patients with germline mutations or family history of breast cancer, please refer to See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic 新增:治疗后监测 Added:Post treatment monitoring ...
[8] NCCN Guidelines Version 4.2024 Breast Cancer [9] N Engl J Med. 2021;384(16):1529-1541. [10] Int J Cancer. 2023 May 15;152(10):2134-2144. [11] Breast Cancer Res Treat. 2024 Nov;208(1):203-214. [12]ESMO...
Patients with a known genetic predisposition to breast cancer p53基因病理突变(利-弗劳梅尼综合征)(2B类)(参见NCCN遗传/家族高风险评定指南:乳腺癌、卵巢癌和胰腺癌) Pathologic p53 mutation (Li-Fraumeni syndrome) (category 2B) (See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovar...
©2022。 版本 2.2022, 01/11/22 © 2022 National Comprehensive Cancer Network® (NCCN®), 保留所有权利. 未经 NCCN 明确书面许可,不得以任何形式对本NCCN Guidelines® 及其插图进行复制。 NCCN Guidelines 版本 2.2022 NCCN Guidelines 索引 目录 胃癌 讨论 NCCN 胃癌指南 2022 年第 2 版较 2022 ...
版权归©2022NationalComprehensiveCancerNetwork,Inc公司所有。NCCNGuidelinesVersion2.2022乳腺癌NCCN乳腺癌小组成员指南更新概要从NCCN乳腺癌指南中删除了小叶原位癌的建议,参见NCCN乳腺筛查和诊断指南非浸润性乳腺癌:导管原位癌(DCIS)检查和初始治疗(DCIS-1)DCIS术后治疗和监测/随访(DCIS-2)浸润性乳腺癌:临床分期,检查(...
[1] 肖玉铃,朱秀之,江一舟,等.三阴性乳腺癌精准治疗研究的新进展与未来展望[J].中国癌症杂志,2022,32(08):669-679. [2] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (2023 Version 3)[internet]; 2023. Available from: https://www.nccn....